JP2023549322A5 - - Google Patents
Info
- Publication number
- JP2023549322A5 JP2023549322A5 JP2023525997A JP2023525997A JP2023549322A5 JP 2023549322 A5 JP2023549322 A5 JP 2023549322A5 JP 2023525997 A JP2023525997 A JP 2023525997A JP 2023525997 A JP2023525997 A JP 2023525997A JP 2023549322 A5 JP2023549322 A5 JP 2023549322A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acid
- region
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152246 | 2020-11-13 | ||
| KR10-2020-0152246 | 2020-11-13 | ||
| PCT/KR2021/016629 WO2022103220A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549322A JP2023549322A (ja) | 2023-11-24 |
| JP2023549322A5 true JP2023549322A5 (https=) | 2024-11-25 |
Family
ID=81601490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525997A Pending JP2023549322A (ja) | 2020-11-13 | 2021-11-15 | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230416714A1 (https=) |
| EP (1) | EP4245310A4 (https=) |
| JP (1) | JP2023549322A (https=) |
| KR (1) | KR20220065720A (https=) |
| CN (1) | CN116419759A (https=) |
| AU (1) | AU2021377712A1 (https=) |
| CA (1) | CA3196264A1 (https=) |
| CO (1) | CO2023006516A2 (https=) |
| IL (1) | IL302857A (https=) |
| MX (1) | MX2023005579A (https=) |
| WO (1) | WO2022103220A1 (https=) |
| ZA (1) | ZA202304536B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230134823A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| AU2018295994B2 (en) * | 2017-07-07 | 2025-02-06 | Hanmi Pharm. Co., Ltd. | Novel therapeutic enzyme fusion protein and use thereof |
| CN111511910B (zh) * | 2017-12-22 | 2024-11-08 | 韩美药品株式会社 | 具有新颖结构的治疗酶融合蛋白及其用途 |
-
2021
- 2021-11-15 US US18/036,538 patent/US20230416714A1/en active Pending
- 2021-11-15 MX MX2023005579A patent/MX2023005579A/es unknown
- 2021-11-15 JP JP2023525997A patent/JP2023549322A/ja active Pending
- 2021-11-15 AU AU2021377712A patent/AU2021377712A1/en active Pending
- 2021-11-15 IL IL302857A patent/IL302857A/en unknown
- 2021-11-15 WO PCT/KR2021/016629 patent/WO2022103220A1/ko not_active Ceased
- 2021-11-15 KR KR1020210156862A patent/KR20220065720A/ko active Pending
- 2021-11-15 CN CN202180075085.8A patent/CN116419759A/zh active Pending
- 2021-11-15 EP EP21892387.8A patent/EP4245310A4/en active Pending
- 2021-11-15 CA CA3196264A patent/CA3196264A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04536A patent/ZA202304536B/en unknown
- 2023-05-17 CO CONC2023/0006516A patent/CO2023006516A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12522641B2 (en) | Targeted mutant interferon-gamma and uses thereof | |
| JP2019137675A5 (https=) | ||
| US20220096596A1 (en) | Method of treating amd in patients refractory to anti-vegf therapy | |
| US12583898B2 (en) | Therapeutic interferon alpha 1 proteins | |
| JP2021533779A5 (https=) | ||
| JP2020508068A5 (https=) | ||
| JP2023181445A5 (https=) | ||
| JP2021512899A5 (https=) | ||
| WO2018028635A1 (zh) | 一种寨卡病毒人源单克隆抗体及其应用 | |
| JP2022526799A (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| JP2022526799A5 (https=) | ||
| KR20150023957A (ko) | 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질 | |
| US20220194993A1 (en) | Flagellin fusion protein and use thereof | |
| JPH07504808A (ja) | Ｃｄｒをグラフトしたヒト化キメラｔ細胞抗体 | |
| US20240199714A1 (en) | Il-2 based constructs | |
| JP2020503262A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2017514515A5 (https=) | ||
| US20140113853A1 (en) | Transducible Polypeptides for Modifying Metabolism | |
| JP2024504777A5 (https=) | ||
| JP2023544211A5 (https=) | ||
| JP2026004299A5 (https=) | ||
| JP2023545707A5 (https=) | ||
| JP2020526497A5 (https=) | ||
| JP2023554379A5 (https=) | ||
| JP2023549322A5 (https=) |